Since its foundation in 2001, GenoScreen has been developing DNA analysis services that meet the needs of life science research groups.
The company’s growth is based on constant R&D investment and strong specialization in molecular microbiology.
This growth summarizes three phases:
- service provision in genomics and bioinformatics, which enabled us to develop relationships with many life science research groups.
- the development of R&D activities, in collaboration with leading research groups.
- the introduction of an innovation strategy, and specialization in international niche markets in molecular microbiology.
This development pathway has enabled GenoScreen to commercialize three types of products/services:
- scientific analyses and monitoring services in genomics and bioinformatics.
- consultancy, expert analysis and training in our fields of expertise.
- innovative kits for the detection and analysis of isolated microorganisms or microbial communities.
- 2001 Foundation
- 2004 GenoScreen launches its in-house R&D activities
- 2005 Our export sales account for over 20% of turnover
- 2006 Our first scientific publication
- 2006 Filing of the first patent
- 2007 GenoScreen files a patent application on OTC biomarkers / MIRU M. tuberculosis typing kit launched
- 2009 Launch of the M. tuberculosis typing kit / Export sales account for over 30% of turnover export
- 2010 Launch of the GenoSat ® microsatellite library service / Initiation of the MEDIALZ project (Alzheimer’s disease)
- 2011 Start of the Patho-Ngen-Trace project (FP7)
- 2012 Implementation of the EQUIPEX technology platform (French government program) / Optimization of the metagenomics services
- 2013 Initiation of industrial R&D collaborations
- 2013 The MIRU-VNTR kit becomes a benchmark for tuberculosis surveillance
- 2014 Launch of the hypervariable MIRU-VNTR kit, used for close surveillance of the Beijing strain – an important target in the molecular surveillance of tuberculosis in Asia
- 2014 Launch of Metabiote®, a standardized method for microbiota analysis
- 2017 Launch of the Deeplex® Myc-TB kits, to counter antibiotic resistance in tuberculosis